ATE214282T1 - Verhinderung der koagulation von blut-, blutplasma- bzw. synovialflüssigkeitsprodukten - Google Patents

Verhinderung der koagulation von blut-, blutplasma- bzw. synovialflüssigkeitsprodukten

Info

Publication number
ATE214282T1
ATE214282T1 AT98928727T AT98928727T ATE214282T1 AT E214282 T1 ATE214282 T1 AT E214282T1 AT 98928727 T AT98928727 T AT 98928727T AT 98928727 T AT98928727 T AT 98928727T AT E214282 T1 ATE214282 T1 AT E214282T1
Authority
AT
Austria
Prior art keywords
blood
citrate
iso
synovial fluid
products
Prior art date
Application number
AT98928727T
Other languages
English (en)
Inventor
Mats Raenby
Original Assignee
Global Hemostasis Inst Mgr Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Hemostasis Inst Mgr Ab filed Critical Global Hemostasis Inst Mgr Ab
Application granted granted Critical
Publication of ATE214282T1 publication Critical patent/ATE214282T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Dentistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT98928727T 1997-06-05 1998-05-29 Verhinderung der koagulation von blut-, blutplasma- bzw. synovialflüssigkeitsprodukten ATE214282T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5292997P 1997-06-05 1997-06-05
PCT/SE1998/001030 WO1998055129A1 (en) 1997-06-05 1998-05-29 Anti-coagulation of blood, blood plasma or synovial fluid products

Publications (1)

Publication Number Publication Date
ATE214282T1 true ATE214282T1 (de) 2002-03-15

Family

ID=21980831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98928727T ATE214282T1 (de) 1997-06-05 1998-05-29 Verhinderung der koagulation von blut-, blutplasma- bzw. synovialflüssigkeitsprodukten

Country Status (10)

Country Link
US (1) US6368785B1 (de)
EP (1) EP0986394B1 (de)
JP (1) JP2001527530A (de)
CN (1) CN1104902C (de)
AT (1) ATE214282T1 (de)
AU (1) AU8045498A (de)
CA (1) CA2292595A1 (de)
DE (1) DE69804216T2 (de)
ES (1) ES2174446T3 (de)
WO (1) WO1998055129A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10206648A1 (de) * 2002-02-15 2003-09-11 November Ag Molekulare Medizin Wirkstoff zur Herstellung eines Stoffs zur Beeinflussung der Koagulationsbereitschaft des Bluts
US20110129857A1 (en) * 2009-11-27 2011-06-02 Msdx, Inc. Methods Of Detecting Or Monitoring Activity Of An Inflammatory Condition Or Neurodegenerative Condition
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
EP2413944B1 (de) 2009-03-31 2017-11-08 Gambro Lundia AB Mehrteiliges fluidsystem und system zur regionalen citrat-antikoagulation in einem extrakorporalen blutkreislauf
MX370297B (es) * 2009-06-17 2019-12-09 Fresenius Medical Care Holdings Inc Procedimientos de diálisis de anticoagulación regional con citrato.
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
CN110361531B (zh) * 2019-08-02 2023-04-11 天津医科大学总医院 一种检测微粒促凝活性的实验方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828976A (en) * 1983-12-29 1989-05-09 Thomas Jefferson University Glucose free media for storing blood platelets
DE3615558A1 (de) 1986-05-09 1987-11-12 Behringwerke Ag Verfahren zur herstellung eines faktor v-konzentrats
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
GB8808004D0 (en) 1988-04-06 1988-05-05 Erdinc A Baby seat

Also Published As

Publication number Publication date
EP0986394B1 (de) 2002-03-13
CA2292595A1 (en) 1998-12-10
DE69804216D1 (de) 2002-04-18
ES2174446T3 (es) 2002-11-01
CN1104902C (zh) 2003-04-09
JP2001527530A (ja) 2001-12-25
EP0986394A1 (de) 2000-03-22
US6368785B1 (en) 2002-04-09
CN1265036A (zh) 2000-08-30
DE69804216T2 (de) 2002-11-07
AU8045498A (en) 1998-12-21
WO1998055129A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
Gutteridge et al. The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper
Friedrichs et al. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart.
AU6933900A (en) Method, reagent and test cartridge for determining clotting time
Gagnon et al. Characterization of a mouse model of chronic uremia
DE3473407D1 (en) Method of inactivating pathogens
DE69907247D1 (de) Verfahren und vorrichtung zum konservieren von biologischen materialien
EP0420332A3 (en) Method for determining the endogenous thrombin potential of plasma and blood, and also a kit or use in said method
JP7027589B2 (ja) 採血管、試薬及びそれらを利用した血液性状分析方法
ATE214282T1 (de) Verhinderung der koagulation von blut-, blutplasma- bzw. synovialflüssigkeitsprodukten
IL94550A0 (en) Process for the storing of erythrocytes and erythrocyte compositions prepared thereby
ATE267518T1 (de) Zusammensetzungen und verfahren zum konservieren von blutplättchen
CA2242693C (en) Additive formulation and method of use thereof
Shen et al. Differential activities of heparins in human plasma and in sheep plasma. Effects of heparin molecular sizes and sources
Plate et al. On the mechanism of enhanced thromboresistance of polymeric materials in the presence of heparin
Quintana et al. Effects of ethanol and of other factors on ADP-induced aggregation of human blood platelets in vitro
Åkerblom et al. Freezing technique and quality of fresh-frozen plasma
Thomas Venous thrombosis and the “Wessler test”
Hunter et al. The effect of poloxamer 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinase
Murphy et al. Endogenous anticoagulation during extracorporeal perfusion: generation of a heparinlike inhibitor
Ts' ao et al. Effect of dextran on platelet activation by polymerizing fibrin.
Col-De Beys et al. Effects of suloctidil on platelet survival time following cardiac valve replacement
Kottke-Marchant et al. The effect of heparin vs. citrate on the interaction of platelets with vascular graft materials
RU2002109172A (ru) Способ прогнозирования клинического течения ишемического инсульта
Lijnen Synthetic substrates in clinical blood coagulation assays
Makowski et al. Interaction of amorphous calcium phosphate with fibrin in vitro causes decreased fibrinolysis and altered protease profiles: implications for atherosclerotic disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties